Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures: 2015-2024

Historic Capital Expenditures for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $5.8 million.

  • Intellia Therapeutics' Capital Expenditures fell 97.73% to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 68.59%. This contributed to the annual value of $5.8 million for FY2024, which is 58.68% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Capital Expenditures is $5.8 million, which was down 58.68% from $14.0 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Capital Expenditures high stood at $14.0 million for FY2023, and its period low was $3.6 million during FY2020.
  • For the 3-year period, Intellia Therapeutics' Capital Expenditures averaged around $11.1 million, with its median value being $13.6 million (2022).
  • As far as peak fluctuations go, Intellia Therapeutics' Capital Expenditures surged by 255.82% in 2021, and later slumped by 58.68% in 2024.
  • Intellia Therapeutics' Capital Expenditures (Yearly) stood at $3.6 million in 2020, then soared by 255.82% to $12.8 million in 2021, then climbed by 6.29% to $13.6 million in 2022, then rose by 3.15% to $14.0 million in 2023, then plummeted by 58.68% to $5.8 million in 2024.